Biogen: Q2 well above consensus
(CercleFinance.com) - Biogen has reported Q2 2019 adjusted net earnings that are up 45% at 1.
74 billion dollars, meaning EPS of 9.15 dollars per share, which is well above the consensus of about 7.50 dollars.
At 3.62 billion dollars, the pharmaceutical company's revenues increased by 8%, in particular supported by the continued global launch of Spinraza, while revenues in multiple sclerosis drugs rose by 3%.
Michel Vounatsos, Biogen's CEO said, “We added four new programs to our pipeline this quarter," two potentially first-in-class mid- to late-stage gene therapy programs in specialty ophthalmology,thanks to the acquisition of Nightstare Therapeutics.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
74 billion dollars, meaning EPS of 9.15 dollars per share, which is well above the consensus of about 7.50 dollars.
At 3.62 billion dollars, the pharmaceutical company's revenues increased by 8%, in particular supported by the continued global launch of Spinraza, while revenues in multiple sclerosis drugs rose by 3%.
Michel Vounatsos, Biogen's CEO said, “We added four new programs to our pipeline this quarter," two potentially first-in-class mid- to late-stage gene therapy programs in specialty ophthalmology,thanks to the acquisition of Nightstare Therapeutics.
Copyright (c) 2019 CercleFinance.com. All rights reserved.